Latest news with #Unichem
Yahoo
31-05-2025
- Business
- Yahoo
Ipca Laboratories Ltd (BOM:524494) Q4 2025 Earnings Call Highlights: Strong Domestic Growth and ...
Domestic Business Growth (Q4): 11% Domestic Business Growth (FY25): 12% Market Share Improvement (Q4): Increased by 9 basis points to 2.07% Overall Market Growth (IQVIA): 8% IPCA Overall Growth (IQVIA): 13.2% Acute Segment Growth (Market): 6.9% IPCA Acute Segment Growth: 10.9% Chronic Segment Growth (Market): 9.8% IPCA Chronic Segment Growth: 17.9% Branded Formulation Business Growth (FY25): 10% (from INR527 crores to INR582 crores) Branded Formulation Business Growth (Q4): 3% Generic Business Growth (Q4): 15% (from INR312 crores to INR357 crores) Generic Business Growth (FY25): 7% (from INR1,248 crores to INR1,336 crores) API Business Growth (Q4): 2% API Business Growth (FY25): 1% Stand-alone EBITDA Margin (Q4): 21.19% (up from 18.5%) Stand-alone EBITDA Margin (FY25): 22.66% (up from 19.29%) Consolidated EBITDA Margin (Q4): 18.24% (up from 14.98%) Consolidated EBITDA Margin (FY25): 18.94% (up from 16.72%) Unichem Consolidated Growth: 18% (from INR1,785 crores to INR2,211 crores) Unichem EBITDA Margin Improvement: From 4.87% to 12.55% Warning! GuruFocus has detected 3 Warning Signs with BOM:524494. Release Date: May 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ipca Laboratories Ltd (BOM:524494) reported a domestic business growth of 11% for Q4 and 12% for the full year, outperforming the overall market growth. The company improved its market share in the chronic segment, with a growth rate of 17.9% compared to the market's 9.8%. Consolidated EBITDA margins improved significantly, reaching 18.94% for FY25, up from 16.72% in FY24. The company's export formulation business, particularly the branded formulation segment, showed a growth of 10% for FY25. Unichem, a subsidiary of Ipca Laboratories Ltd, delivered a consolidated growth of 18% and improved its EBITDA margin from 4.87% to 12.55%. The generic business in South Africa saw a significant decline of 74% due to the loss of certain tenders. The US market contribution was minimal, with only INR 22-23 crores in sales, indicating a slow ramp-up in this region. The CIS market growth was muted at 2% due to currency fluctuations, impacting the overall value growth. The company's API business showed minimal growth, with only a 1% increase for the full financial year. There was a decline in the Middle East and Africa markets by 21%, affecting the overall branded generic business. Q: What is the contribution of the US business to IPCA's overall revenue, and what are the future expectations? A: Ajit Jain, CFO and Managing Director, stated that the US market has not significantly contributed to the overall business, with shipments worth around INR 65 crores. However, the expectation for the current financial year is that the US business will contribute around INR 100 crores. Q: How is the integration of Unichem impacting R&D and what are the future plans? A: Ajit Jain explained that IPCA has started filing new products and plans to file around 6 to 7 products this year. The R&D expenditure is expected to be around 4% of revenue. Unichem's R&D remains independent, focusing on market extensions and filings. Q: Can you provide insights into the export market performance and future growth expectations? A: The company representative noted that the branded formulation business grew by 10%, with significant growth in West Africa (34%) and Southeast Asia (24%). The generic business, including institutional sales, is expected to grow by 10% in the current financial year. Q: What is the status of new manufacturing projects and their expected impact? A: Four new manufacturing facilities are expected to start trial production in the current financial year, including a monoclonal antibody facility and a new formulation facility for the domestic market. These are expected to scale up in FY27 and FY28. Q: What are the expectations for Unichem's performance and integration benefits? A: Unichem has achieved a growth of 18% in revenue and improved EBITDA margins. The integration benefits are expected to start yielding results from the current financial year, with further margin improvements anticipated. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
20-05-2025
- Business
- Time of India
Samir Mehta's son Aman named MD of Torrent Pharma
MUMBAI: Torrent Pharma has named Aman Mehta , the older son of chairman Samir Mehta , as MD, solidifying the succession plan at the flagship of the $5.3 billion Torrent Group . His new role will begin on August 1. This appears to be the company's first MD position. Aman, 33, who represents the third generation of the family, joined the company's board as a director in 2022. His younger brother Shaan Mehta, 27, currently leads strategy at the company. The Torrent Group, founded by Aman and Shaan's grandfather in 1959, now has diverse interests spanning from pharmaceuticals to power. Their cousin, Jinal Mehta, currently serves as the vice chairman and MD of Torrent Power. ' As part of our long-term strategic vision and succession planning, the board has approved the appointment of Aman Mehta as MD, effective August 1, 2025,' said Torrent Pharma, adding that 'This appointment is aligned with our commitment to building a strong, future-ready leadership team capable of delivering sustainable value to all stakeholders.' An economics graduate from Boston University with an MBA from Columbia University, Aman joined the Torrent Group in October 2013. His career spans leadership positions across the group's pharma and power businesses. A notable accomplishment includes overseeing the integration of Unichem's domestic operations into Torrent Pharma. The company acquired Unichem's 120 brands and manufacturing facility for Rs 3,600 crore in December 2017. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
NZ Herald
16-05-2025
- Health
- NZ Herald
Measles alert: 78 quarantined, hundreds traced as Auckland case sparks concern
About 80% of New Zealanders are immune, well below the 95% coverage needed to prevent an outbreak. HNZ said it had reached out to 286 close contacts since and 78 of those people are in quarantine as a precautionary measure. So far, 19 of the close contacts are waiting for blood test results to confirm their measles immunity status. HNZ said it had offered and encouraged MMR vaccinations to anyone identified in the process as non-immune. The agency said it had delivered 50 food packages to people in quarantine who could not access food. HNZ has confirmed 17 exposure events across Auckland – most of which took place on Fullers360 ferry sailings between Auckland CBD, Devonport, Rangitoto and Half Moon Bay on May 5. Other locations include a CBD carpark on Customs St, Unichem pharmacy in New Lynn, a Pak'nSave supermarket in Mt Albert, and a Woolworths supermarket in Kelston. The national clinical director of protection at the National Public Health Service, Dr Susan Jack, said its staff had been making phone calls, sending texts and emails, and in some cases door knocking to follow up on close contacts. She said the virus was highly contagious and an infected person can infect as many as 12 to 18 other people on average. 'Our teams have focused on moving as quickly as possible to reduce the spread,' she said. Jack said anyone identified as non-immune during the contact tracing process has been asked to quarantine. 'Vaccination with two doses of the MMR vaccine remains the absolute best protection against becoming seriously unwell with measles. ' The vaccine is 99% effective after two doses and for most people there's no risk in having an extra dose if it's needed. Now is the time for you and your whānau to check if you're protected against measles, and to get immunised if you're not, or if you're unsure.' She said it was especially important for infants and young children, and adults who were born or lived in New Zealand between 1969 and 2004 (now aged between 21 and 56), who may not be fully protected, to check their immunisation status. Jack also encouraged anyone planning to travel internationally to make sure they were vaccinated against measles because of the risks of outbreaks in many countries.
RNZ News
13-05-2025
- Health
- RNZ News
Measles case returned to New Zealand from Asia on 29 April
Health New Zealand says the person with measles who returned from Asia became infectious on 2 May. Photo: RNZ /Dom Thomas Health New Zealand has confirmed that the measles case in Auckland had returned to New Zealand from Asia on 29 April. The agency says the person first became infectious from 2 May. According to a list released by Health NZ, the earliest location visited by the case was a Woolworths supermarket in Kelston, on 3 May between 2.30pm and 4.30pm. Last Monday (5 May), the person worked as a crew member on a number of Fullers ferry sailings between Auckland City, Devonport, Half Moon Bay and Rangitoto. Only those people who travelled between 3.30pm and 7.40pm on 5 May and who used the toilets on the ferries are considered close contacts, but anyone who travelled on the ferries at those times should watch for symptoms. Anyone who sailed on the ferries between 9pm and 9.45pm on 5 May is considered a close contact. Also considered a close contact is anyone who used the stairs in the Auckland Downtown Carpark on Customs Street between 1.30pm and 2.30pm on 5 May and anyone who used the carpark's lift between 11pm and midnight that day. And last Wednesday (7 May), the person visited a Unichem pharmacy in New Lynn between 9am and 10.30am, and a Pak 'n Save supermarket in Mount Albert between 10am and 11.45am. Anyone who was in those stores at those times is considered a close contact. Health NZ said it was unlikely there would be any further locations linked to the case. Measles symptoms usually started within 10 to 14 days of being exposed to the virus and the rash developed three to four days after other symptoms such as fever, sore red eyes and a cough and runny nose, Health NZ advised. People who were close contacts should contact Healthline on 0800 611 116 urgently, check whether they were immune to measles and monitor for symptoms of measles, it said. Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
12-05-2025
- Health
- RNZ News
Auckland measles case: New locations of interest include chemist, second supermarket
File photo. Photo: RNZ /Dom Thomas An Auckland pharmacy and a second supermarket have been named as places a recent case of measles visited while infectious. Health NZ Te Whatu Ora said yesterday that a case of measles had been identified in Auckland, and named several locations of interest, including multiple ferry journeys and a West Auckland supermarket. In a statement this afternoon, Health NZ revealed more places the person with measles had visited while infectious. The details of the new locations are the Unichem pharmacy in New Lynn on 7 May between 9am and 10.30am, and the Mount Albert Pak n Save on 7 May between 10am and 11.45am Anyone who was at these locations at these times need to check they have immunity to measles, said Health NZ. - more to come
